AZN Share Price

Open 4028.50 Change Price %
High 4201.50 1 Day 103.50 2.58
Low 4011.00 1 Week 41.00 1.01
Close 4110.50 1 Month -335.50 -7.55
Volume 2928025 1 Year -349.50 -7.84
52 Week High 5505.00
52 Week Low 3680.00
AZN Important Levels
Resistance 2 4287.09
Resistance 1 4214.32
Pivot 4107.67
Support 1 4006.68
Support 2 3933.91
LON UK Most Active Stocks
LGO 0.14 0.00%
LGO 0.14 0.00%
LGO 0.14 0.00%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 62.56 0.47%
GKP 1.30 7.44%
FCR 0.25 -10.71%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
BAF 105.00 133.33%
BAF 105.00 133.33%
BAF 105.00 133.33%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
BAC 22.87 63.36%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

AstraZeneca PLC (LON: AZN)

AZN Technical Analysis 4
As on 8th Dec 2016 AZN Share Price closed @ 4110.50 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4401.14 & Strong Sell for SHORT-TERM with Stoploss of 4612.21 we also expect STOCK to react on Following IMPORTANT LEVELS.
AZN Target for December
1st Target up-side 4486.59
2nd Target up-side 4717.61
3rd Target up-side 4948.63
1st Target down-side 3827.41
2nd Target down-side 3596.39
3rd Target down-side 3365.37
AZN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.astrazeneca.com
AZN Address
AZN
2 Kingdom Street
London, W2 6BD
United Kingdom
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151
Interactive Technical Analysis Chart AstraZeneca PLC ( AZN LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AstraZeneca PLC
AZN Business Profile
AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.